Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to compare the safety and efficacy of 2 higher tigecycline dose regimens with that of the imipenem/cilastatin regimen in order to determine the dose(s) of tigecycline that will be tolerable and non-inferior to imipenem/cilastatin in treating subjects with HAP.
Critère d'inclusion
- Hospital-Acquired Pneumonia (HAP) including Ventilator-Associated Pneumonia (VAP)